◎ Sugi Atlas

Atlas / Drug / Oxygen

Oxygen

drug
On this page

Also known as DioxygenE-948E948INS NO.948INS-948Medicinal oxygen air liquide santeMolecular oxygenOxygen 93 percentOXYGEN COMPONENT OF RNS-60OXYGEN COMPONENT OF RNS60Oxygen moleculeOxygenium

Summary

Oxygen (CHEMBL1234886) is an approved small-molecule anti-inflammatory drug (ATC V03AN01) targeting TRPA1; indicated across 88 conditions including chronic obstructive pulmonary disease and acute kidney injury.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: V03AN01
  • Targets: 1 (TRPA1)
  • Indications: 88 conditions
  • Clinical trials: 426
  • Chemistry: 31.999 Da · O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1234886
NameOxygen
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID977
ChEBICHEBI:15379
ATCV03AN01
Molecular formulaO2
Molecular weight31.999
InChIKeyMYMOFIZGZYHOMD-UHFFFAOYSA-N

SMILES: O=O

IUPAC name: molecular oxygen

Pharmacological roles (ChEBI): anti-inflammatory drug, nutrient, micronutrient, oxidising agent.

Other ChEBI roles (chemical / environmental): reagent, human metabolite, food packaging gas, Saccharomyces cerevisiae metabolite.

Also known as: Dioxygen, E-948, E948, INS NO.948, INS-948, Medicinal oxygen air liquide sante, Molecular oxygen, Oxygen, Oxygen 93 percent, OXYGEN COMPONENT OF RNS-60, OXYGEN COMPONENT OF RNS60, Oxygen molecule

Patent coverage: 3,090,579 distinct patent families (6,302,653 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 6,300,907 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
TRPA1TRPA1Activation5.50.1%O75762

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): TRPA1.

Top Reactome pathways

1 total, by targets touching each:

PathwayTargetsGenes
TRP channels1TRPA1

Dominant GO biological processes

GO termTargets
monoatomic ion transport1
intracellular calcium ion homeostasis1
cell surface receptor signaling pathway1
response to cold1
response to xenobiotic stimulus1
urinary bladder smooth muscle contraction1
sensory perception of pain1
cellular response to heat1
positive regulation of insulin secretion involved in cellular response to glucose stimulus1
response to pain1
thermoception1
detection of mechanical stimulus involved in sensory perception of pain1
detection of chemical stimulus involved in sensory perception of pain1
protein homotetramerization1
cellular response to hydrogen peroxide1

Indications & clinical

Indications

88 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
chronic obstructive pulmonary disease3MONDO:0005002EFO:0000341
acute kidney injury3MONDO:0002492HP:0001919
diabetes mellitus3MONDO:0005015EFO:0000400
vascular disorder3MONDO:0005385EFO:0004264
heart failure3MONDO:0005252EFO:0003144
acute respiratory distress syndrome3MONDO:0006502EFO:1000637
anterior ischemic optic neuropathy3MONDO:0006649EFO:1000809
retinopathy of prematurity3MONDO:0006952EFO:1001158
pulmonary embolism3MONDO:0005279EFO:0003827
coronary artery disorder3MONDO:0005010EFO:0001645
burn3MONDO:0043519EFO:0009516
pulmonary arterial hypertension3MONDO:0015924EFO:0001361
pneumonia3MONDO:0005249EFO:0003106
complex regional pain syndrome3MONDO:0019369EFO:1001998
bronchiolitis3MONDO:0002465HP:0011950
ulcer disease3MONDO:0043839MONDO:0043839
bone fracture3MONDO:0005315EFO:0003931
pyoderma3MONDO:0002922HP:0000999
sickle cell disease3MONDO:0011382MONDO:0011382
pulmonary hypertension3MONDO:0005149MONDO:0005149
long COVID-193MONDO:0100233MONDO:0100233
injury2MONDO:0021178EFO:0000546
idiopathic pulmonary fibrosis2MONDO:0800504EFO:0000768
ulcerative colitis2MONDO:0005101EFO:0000729
plasma cell myeloma2MONDO:0009693EFO:0001378
obstructive sleep apnea syndrome2MONDO:0007147EFO:0003918
opiate dependence2MONDO:0005530EFO:0005611
tinea pedis2MONDO:0005984EFO:0007512
gliosarcoma2MONDO:0016681EFO:1001465
osteoradionecrosis2MONDO:0043735EFO:1001821
head and neck squamous cell carcinoma2MONDO:0010150EFO:0000181
autism spectrum disorder2MONDO:0005258EFO:0003756
status asthmaticus2MONDO:0004766EFO:0008590
pulmonary fibrosis2MONDO:0002771EFO:0009448
severe acute respiratory syndrome2MONDO:0005091EFO:0000694
stroke disorder2MONDO:0005098EFO:0000712
laryngeal neoplasm2MONDO:0021071MONDO:0002358
breast neoplasm2MONDO:0021100MONDO:0007254
brain injury2MONDO:0043510MONDO:0043510
endocarditis2MONDO:0005025EFO:0000465
post-traumatic stress disorder2MONDO:0005146EFO:0001358
acute myocardial infarction2MONDO:0004781EFO:0008583
migraine disorder2MONDO:0005277MONDO:0005277
lymphedema2MONDO:0019297MONDO:0019297
cystitis2MONDO:0006032EFO:1000025
myocardial ischemia2MONDO:0024644EFO:1001375
neoplasm2MONDO:0005070MONDO:0004992
tonsillitis2MONDO:0001039MONDO:0001039
brain cancer2MONDO:0001657MONDO:0001657
erectile dysfunction1MONDO:0005362EFO:0004234
ischemic disease1MONDO:0005053EFO:0000556
osteonecrosis1MONDO:0005380EFO:0004259
non-small cell lung carcinoma1MONDO:0005233EFO:0003060
autism1MONDO:0005260EFO:0003758
brain disorder1MONDO:0005560EFO:0005774
respiratory failure1MONDO:0021113EFO:0009842
central nervous system neoplasm1MONDO:0006130EFO:1000158
ischemia reperfusion injury1MONDO:0005203EFO:0002687
ileus1MONDO:0004567MONDO:0004567
type 2 diabetes mellitus1MONDO:0005148MONDO:0005148
hypoplastic left heart syndrome1MONDO:0004933MONDO:0004933
inflammatory bowel disease1MONDO:0005265EFO:0003767
lung neoplasm1MONDO:0021117MONDO:0008903
neuralgia0MONDO:0021667EFO:0005762
anxiety0MONDO:0011918EFO:0005230
lung disorder0MONDO:0005275EFO:0003818
Bell’s palsy0MONDO:0005665EFO:0007167
spinal cord injury0MONDO:0043797EFO:1001919
retinitis pigmentosa0MONDO:0019200MONDO:0019200

19 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 426.

Phase distribution

PhaseTrials
Not specified242
PHASE456
PHASE248
PHASE336
PHASE115
PHASE2/PHASE313
PHASE1/PHASE28
EARLY_PHASE18

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02703220PHASE4RECRUITINGSleep Apnea in Elderly
NCT02922894PHASE4RECRUITINGTreatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury
NCT03144206PHASE4ACTIVE_NOT_RECRUITINGHyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
NCT03552627PHASE4ACTIVE_NOT_RECRUITINGPerioperative UtiLisation of SupplEmental Oxygen
NCT05344274PHASE4RECRUITINGRetinal Blood Flow and Autoregulation
NCT05703919PHASE4RECRUITINGStandard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease
NCT05804097PHASE4ACTIVE_NOT_RECRUITINGDoes Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?
NCT07210606PHASE4NOT_YET_RECRUITINGCentral Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment
NCT07240649PHASE4NOT_YET_RECRUITINGOutcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
NCT07280468PHASE4RECRUITINGEndotype DIrected Treatment for OSA in Down Syndrome
NCT07384403PHASE4RECRUITINGApplication of Topical Oxygen Therapy Around Customized Healing Collar
NCT00364741PHASE4COMPLETEDSupplemental Oxygen and Complications After Abdominal Surgery (The PROXI-trial)
NCT00637936PHASE4COMPLETEDRespiratory Effects of Perioperative Oxygen During General Anaesthesia
NCT00732537PHASE4COMPLETEDInhaled Nitric Oxide by Oxygen Hood in Neonates
NCT00958178PHASE4UNKNOWNA Novel Method of Preoxygenation Using a Bain Circuit
NCT01057420PHASE4COMPLETEDEffect of Hyperoxemia on Platelet Function in Healthy Volunteers
NCT01180192PHASE4UNKNOWNPostpartum Oxygen Inhalation for the Treatment of Postpartum Haemorrhage
NCT01216553PHASE4UNKNOWNHome Oxygen Therapy in Bronchiolitis
NCT01319643PHASE4UNKNOWNNormal Oxygenation Versus Hyperoxia in the Intensive Care Unit (ICU)
NCT01423929PHASE4COMPLETEDSupplemental Oxygen in Catheterized Coronary Emergency Reperfusion
NCT01715584PHASE4UNKNOWNIs There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics
NCT01722370PHASE4COMPLETEDAmbulatory Oxygen Effects on Muscles in COPD
NCT01725464PHASE4COMPLETEDThe Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy
NCT02143609PHASE4COMPLETEDPatients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Exercise Performance
NCT02143687PHASE4COMPLETEDPatients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance
NCT02150590PHASE4COMPLETEDPatients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Breathing and Sleep
NCT02150616PHASE4UNKNOWNPatients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep
NCT02243826PHASE4UNKNOWNImpact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial
NCT02246023PHASE4COMPLETEDFractionated Versus Target-controlled Propofol Administration in Bronchoscopy
NCT02273830PHASE4COMPLETEDBenefits of Liquid Oxygen in COPD Patients Presenting Desaturation During Exercise.
NCT02286063PHASE4COMPLETEDAmbulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)
NCT02321072PHASE4COMPLETEDOptimal Oxygenation in the Intensive Care Unit
NCT02378545PHASE4COMPLETEDTrial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis
NCT02509182PHASE4WITHDRAWNThe Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy
NCT02573987PHASE4COMPLETEDMEOPA Versus Local Anesthesia for Analgesia During Chorionic Villus Sampling.
NCT02703233PHASE4WITHDRAWNEffectiveness of Nitrous Oxide in the ED
NCT02910765PHASE4UNKNOWNMethylene Blue and Ozone in Early Sepsis
NCT03015051PHASE4TERMINATEDHigh Flow Nasal Cannula vs Low Flow Oxygen Therapy in Bronchiolitis
NCT03174002PHASE4COMPLETEDHandling Oxygenation Targets in the Intensive Care Unit
NCT03228628PHASE4UNKNOWNNitrous Oxide for Lumbar Puncture

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

27 molecules share ≥1 primary target. Top 27 by shared-target count:

MoleculeSourceStatusShared targets
DICLOFENACChEMBL + PubChemPhase 4 (approved)TRPA1
DISULFIRAMChEMBL + PubChemPhase 4 (approved)TRPA1
MEFENAMIC ACIDChEMBL + PubChemPhase 4 (approved)TRPA1
MENTHOLChEMBLPhase 4 (approved)TRPA1
NICOTINEChEMBLPhase 4 (approved)TRPA1
RESVERATROLChEMBL + PubChemPhase 3 (approved)TRPA1
CANNABINOLChEMBLPhase 3TRPA1
ICILLINChEMBLPhase 3TRPA1
LEVOMENTHOLChEMBLPhase 3TRPA1
ALLICINChEMBLPhase 2TRPA1
CANNABIDIVARINChEMBLPhase 2TRPA1
CANNABIGEROLChEMBLPhase 2TRPA1
CARVACROLChEMBLPhase 2TRPA1
CHLORDANTOINChEMBLPhase 2TRPA1
FLUFENAMIC ACIDChEMBLPhase 2TRPA1
RG6341ChEMBLPhase 2TRPA1
SALIRASIBChEMBLPhase 2TRPA1
SANGUINARIUMChEMBLPhase 2TRPA1
TETRAHYDROCANNABIVARINChEMBLPhase 2TRPA1
THYMOLChEMBLPhase 2TRPA1
AcetaldehydePubChemApprovedTRPA1
CaffeinePubChemApprovedTRPA1
camphor (synthetic)PubChemApprovedTRPA1
dronabinolPubChemApprovedTRPA1
EugenolPubChemApprovedTRPA1
menthol, unspecified formPubChemApprovedTRPA1
Propylene GlycolPubChemApprovedTRPA1

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot